Skip to main content
. 2016 Aug 12;7(38):61806–61819. doi: 10.18632/oncotarget.11241

Figure 7. Clinical significance of PRIMA-1 treatment.

Figure 7

A. Cell viability of primary patient samples when they were treated with increasing dosage of PRIMA-1 for 48 hours. B. Patient samples were treated with PRIMA-1 and protein expression of p53 and PARP was examined by Western blot analysis. C. Samples from patient N073 and T019 were treated with PRIMA-1 for 24 hours and cells were harvested for Western blot analysis probing for HSP70, CHOP, GADD34 and NOXA. D. Cell viability of 8226-P100V after treatment with either a fixed dosage of PRIMA-1 (40uM), increasing dosage of bortezomib (25nM, 50nM, 100nM) or combination of PRIMA-1 40uM with the corresponding bortezomib dosage on the x-axis. E. Percentage specific apoptosis of P100V after PRIMA-1 or/and bortezomib treatment. 1- Untreated, 2- PRIMA-1 (48h), 3-Bortezomib (48h), 4- Combination of PRIMA-1 and Bortezomib (48h), 5- To test for re-sensitization to bortezomib, P100V were treated with PRIMA-1 (25uM) for 6 hours and the cells were washed twice with PBS and were allowed to recover in normal culture medium till harvesting, 6- P100V were treated with PRIMA-1 (25uM) for 6 hours and the cells were washed twice with PBS and were allowed to recover in normal culture medium overnight. These cells were subsequently treated with bortezomib (25nM) for 48 hours. O/N: overnight. F. Cell viability of JJN3 after 48 hours treatment with either fixed low dosage of PRIMA-1 (10uM), increasing dosage of bortezomib or combination of PRIMA-1 (10uM) with the corresponding bortezomib dosage on the x-axis. G. JJN3 were treated with either PRIMA-1 (25uM), or bortezomib (5nM) or combination of both. Cells were harvested to check for the protein expression of the UPR markers. H. The mRNA level of UPR markers in JJN3 after treatment with either PRIMA-1 (25uM), or bortezomib (5nM) or combination of both. * p < 0.05, ** p < 0.01.